Skip to main content
. Author manuscript; available in PMC: 2014 Dec 1.
Published in final edited form as: Mol Cancer Ther. 2013 Oct 15;12(12):10.1158/1535-7163.MCT-13-0547. doi: 10.1158/1535-7163.MCT-13-0547

Figure 1. EVRi inhibits tumor growth and progression of ovarian cancer xenografts.

Figure 1

(A) Tumor growth curves for mice bearing intraperitoneal SKOV3.ip1-LUC xenografts treated with HERi, VEGFRi, EVRi, or saline control. Representative bioluminescent images for each of the treatment groups at 35 days post tumor inoculation. In addition, final tumor weight (C), correlation between bioluminescence and actual tumor weight (D), and progression-free survival (PFS) (E) are depicted. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.